NURS 6521 FINAL EXAM V3 – ADVANCED PHARMACOLOGY FINAL EXAM
WALDEN UNIVERSITY | EXAM PRACTICE | STUDY GUIDE | TESTBANK | PRACTICE
QUESTIONS & ANSWERS | EXAM PREPARATION | LATEST UPDATE 2026/2027 |
ADVANCED REVIEW | COMPREHENSIVE PRACTICE EXAM
Examiner:
Walden University
## TABLE OF CONTENTS
1. Principles of Advanced Pharmacokinetics and Pharmacodynamics
2. Drug Metabolism and Pharmacogenomics
3. Cardiovascular Pharmacology
4. Endocrine Pharmacology
5. Infectious Disease Pharmacotherapy
6. Neurologic and Psychiatric Pharmacology
7. Respiratory Pharmacology
8. Renal and Gastrointestinal Pharmacology
9. Women's and Men's Health Pharmacology
10. Pain Management and Controlled Substances
11. Special Populations and Geriatric Pharmacology
12. Evidence-Based Prescribing and Clinical Decision-Making
## DESCRIPTION
This comprehensive practice study guide is designed for learners preparing for an
advanced pharmacology final examination covering graduate-level concepts
commonly emphasized in advanced nursing curricula. The questions focus on
applying pharmacologic principles to realistic clinical scenarios involving medication
selection, therapeutic monitoring, adverse drug reactions, drug interactions,
pharmacogenomics, and patient-specific prescribing considerations. Learners are
challenged to analyze complex patient cases, evaluate contraindications, interpret
laboratory findings, and make evidence-informed treatment decisions across multiple
body systems. These practice questions encourage critical thinking rather than
memorization and reflect the breadth of topics typically studied in advanced
pharmacology courses. They are intended solely as an educational resource to
,strengthen clinical reasoning, reinforce core concepts, and support comprehensive
examination preparation.
QUESTION 1.
A 69-year-old patient with heart failure with reduced ejection fraction develops a
persistent dry cough two months after initiating lisinopril. Blood pressure is
controlled, renal function is stable, and serum potassium is normal. Which
medication change best maintains mortality benefit while minimizing recurrence of
the adverse effect?
A. Discontinue lisinopril and initiate losartan.
B. Replace lisinopril with hydralazine monotherapy.
C. Substitute nifedipine extended-release.
D. Replace lisinopril with hydrochlorothiazide.
🔴 Correct Answer: A. Discontinue lisinopril and initiate losartan.
🔵 Explanation: ACE inhibitor-induced cough is related to bradykinin accumulation
and commonly resolves after discontinuation. An angiotensin receptor blocker
provides comparable blockade of the renin-angiotensin system with a substantially
lower incidence of cough while preserving important cardiovascular benefits. The
remaining options do not provide equivalent neurohormonal blockade or mortality
benefit in this setting.
QUESTION 2.
A patient with atrial fibrillation is prescribed warfarin. Two weeks later,
trimethoprim-sulfamethoxazole is started for a urinary tract infection. Which clinical
response is most appropriate?
A. Increase the warfarin dose immediately.
B. Anticipate an increased INR and monitor closely with dose adjustment as needed.
C. Continue both medications without additional monitoring.
D. Add aspirin to reduce thromboembolic risk.
,🔴 Correct Answer: B. Anticipate an increased INR and monitor closely with dose
adjustment as needed.
🔵 Explanation: Trimethoprim-sulfamethoxazole inhibits warfarin metabolism and
increases anticoagulant activity, frequently leading to elevated INR values and
bleeding risk. Close monitoring with individualized dose modification is appropriate.
Increasing the dose or adding aspirin increases bleeding risk, while ignoring the
interaction may result in significant over-anticoagulation.
QUESTION 3.
A patient with type 2 diabetes, chronic kidney disease, and albuminuria requires
additional glucose-lowering therapy despite metformin. Which medication offers
the greatest combined glycemic, renal, and cardiovascular benefit?
A. Sulfonylurea
B. DPP-4 inhibitor
C. SGLT2 inhibitor
D. Meglitinide
🔴 Correct Answer: C. SGLT2 inhibitor
🔵 Explanation: SGLT2 inhibitors improve glycemic control while reducing
progression of chronic kidney disease and lowering the risk of cardiovascular events in
appropriately selected patients. Sulfonylureas and meglitinides primarily improve
glucose levels without comparable cardiorenal protection. DPP-4 inhibitors have more
neutral cardiovascular and renal outcomes.
QUESTION 4.
A patient receiving digoxin reports nausea, blurred vision, and yellow halos around
lights. Laboratory testing reveals hypokalemia. Which interpretation is most
accurate?
A. Digoxin toxicity is less likely because potassium is low.
B. Hypokalemia increases myocardial sensitivity to digoxin toxicity.
, C. The symptoms are most consistent with hypercalcemia alone.
D. Digoxin toxicity occurs only when serum digoxin exceeds the therapeutic range.
🔴 Correct Answer: B. Hypokalemia increases myocardial sensitivity to digoxin
toxicity.
🔵 Explanation: Low potassium enhances digoxin binding to the sodium-potassium
ATPase pump, increasing the likelihood of toxicity even when serum digoxin
concentrations appear therapeutic. Symptoms such as gastrointestinal distress and
visual disturbances are classic findings. Toxicity depends on both serum concentration
and patient susceptibility.
QUESTION 5.
A patient with epilepsy stabilized on phenytoin begins taking a medication that
strongly induces hepatic CYP450 enzymes. Which pharmacokinetic outcome is most
likely for another drug metabolized by the same pathway?
A. Reduced metabolism and increased serum concentration.
B. Enhanced metabolism with decreased therapeutic concentration.
C. No significant pharmacokinetic effect.
D. Complete elimination of first-pass metabolism.
🔴 Correct Answer: B. Enhanced metabolism with decreased therapeutic
concentration.
🔵 Explanation: Enzyme induction accelerates hepatic metabolism of susceptible
medications, often lowering plasma drug concentrations and reducing therapeutic
efficacy. Dose adjustment or alternative therapy may be required. Enzyme induction
does not eliminate first-pass metabolism nor consistently increase serum drug levels.
QUESTION 6.
A patient treated with linezolid develops agitation, tremor, hyperreflexia,
diaphoresis, and fever after continuing sertraline therapy. Which pharmacologic
mechanism best explains these findings?
WALDEN UNIVERSITY | EXAM PRACTICE | STUDY GUIDE | TESTBANK | PRACTICE
QUESTIONS & ANSWERS | EXAM PREPARATION | LATEST UPDATE 2026/2027 |
ADVANCED REVIEW | COMPREHENSIVE PRACTICE EXAM
Examiner:
Walden University
## TABLE OF CONTENTS
1. Principles of Advanced Pharmacokinetics and Pharmacodynamics
2. Drug Metabolism and Pharmacogenomics
3. Cardiovascular Pharmacology
4. Endocrine Pharmacology
5. Infectious Disease Pharmacotherapy
6. Neurologic and Psychiatric Pharmacology
7. Respiratory Pharmacology
8. Renal and Gastrointestinal Pharmacology
9. Women's and Men's Health Pharmacology
10. Pain Management and Controlled Substances
11. Special Populations and Geriatric Pharmacology
12. Evidence-Based Prescribing and Clinical Decision-Making
## DESCRIPTION
This comprehensive practice study guide is designed for learners preparing for an
advanced pharmacology final examination covering graduate-level concepts
commonly emphasized in advanced nursing curricula. The questions focus on
applying pharmacologic principles to realistic clinical scenarios involving medication
selection, therapeutic monitoring, adverse drug reactions, drug interactions,
pharmacogenomics, and patient-specific prescribing considerations. Learners are
challenged to analyze complex patient cases, evaluate contraindications, interpret
laboratory findings, and make evidence-informed treatment decisions across multiple
body systems. These practice questions encourage critical thinking rather than
memorization and reflect the breadth of topics typically studied in advanced
pharmacology courses. They are intended solely as an educational resource to
,strengthen clinical reasoning, reinforce core concepts, and support comprehensive
examination preparation.
QUESTION 1.
A 69-year-old patient with heart failure with reduced ejection fraction develops a
persistent dry cough two months after initiating lisinopril. Blood pressure is
controlled, renal function is stable, and serum potassium is normal. Which
medication change best maintains mortality benefit while minimizing recurrence of
the adverse effect?
A. Discontinue lisinopril and initiate losartan.
B. Replace lisinopril with hydralazine monotherapy.
C. Substitute nifedipine extended-release.
D. Replace lisinopril with hydrochlorothiazide.
🔴 Correct Answer: A. Discontinue lisinopril and initiate losartan.
🔵 Explanation: ACE inhibitor-induced cough is related to bradykinin accumulation
and commonly resolves after discontinuation. An angiotensin receptor blocker
provides comparable blockade of the renin-angiotensin system with a substantially
lower incidence of cough while preserving important cardiovascular benefits. The
remaining options do not provide equivalent neurohormonal blockade or mortality
benefit in this setting.
QUESTION 2.
A patient with atrial fibrillation is prescribed warfarin. Two weeks later,
trimethoprim-sulfamethoxazole is started for a urinary tract infection. Which clinical
response is most appropriate?
A. Increase the warfarin dose immediately.
B. Anticipate an increased INR and monitor closely with dose adjustment as needed.
C. Continue both medications without additional monitoring.
D. Add aspirin to reduce thromboembolic risk.
,🔴 Correct Answer: B. Anticipate an increased INR and monitor closely with dose
adjustment as needed.
🔵 Explanation: Trimethoprim-sulfamethoxazole inhibits warfarin metabolism and
increases anticoagulant activity, frequently leading to elevated INR values and
bleeding risk. Close monitoring with individualized dose modification is appropriate.
Increasing the dose or adding aspirin increases bleeding risk, while ignoring the
interaction may result in significant over-anticoagulation.
QUESTION 3.
A patient with type 2 diabetes, chronic kidney disease, and albuminuria requires
additional glucose-lowering therapy despite metformin. Which medication offers
the greatest combined glycemic, renal, and cardiovascular benefit?
A. Sulfonylurea
B. DPP-4 inhibitor
C. SGLT2 inhibitor
D. Meglitinide
🔴 Correct Answer: C. SGLT2 inhibitor
🔵 Explanation: SGLT2 inhibitors improve glycemic control while reducing
progression of chronic kidney disease and lowering the risk of cardiovascular events in
appropriately selected patients. Sulfonylureas and meglitinides primarily improve
glucose levels without comparable cardiorenal protection. DPP-4 inhibitors have more
neutral cardiovascular and renal outcomes.
QUESTION 4.
A patient receiving digoxin reports nausea, blurred vision, and yellow halos around
lights. Laboratory testing reveals hypokalemia. Which interpretation is most
accurate?
A. Digoxin toxicity is less likely because potassium is low.
B. Hypokalemia increases myocardial sensitivity to digoxin toxicity.
, C. The symptoms are most consistent with hypercalcemia alone.
D. Digoxin toxicity occurs only when serum digoxin exceeds the therapeutic range.
🔴 Correct Answer: B. Hypokalemia increases myocardial sensitivity to digoxin
toxicity.
🔵 Explanation: Low potassium enhances digoxin binding to the sodium-potassium
ATPase pump, increasing the likelihood of toxicity even when serum digoxin
concentrations appear therapeutic. Symptoms such as gastrointestinal distress and
visual disturbances are classic findings. Toxicity depends on both serum concentration
and patient susceptibility.
QUESTION 5.
A patient with epilepsy stabilized on phenytoin begins taking a medication that
strongly induces hepatic CYP450 enzymes. Which pharmacokinetic outcome is most
likely for another drug metabolized by the same pathway?
A. Reduced metabolism and increased serum concentration.
B. Enhanced metabolism with decreased therapeutic concentration.
C. No significant pharmacokinetic effect.
D. Complete elimination of first-pass metabolism.
🔴 Correct Answer: B. Enhanced metabolism with decreased therapeutic
concentration.
🔵 Explanation: Enzyme induction accelerates hepatic metabolism of susceptible
medications, often lowering plasma drug concentrations and reducing therapeutic
efficacy. Dose adjustment or alternative therapy may be required. Enzyme induction
does not eliminate first-pass metabolism nor consistently increase serum drug levels.
QUESTION 6.
A patient treated with linezolid develops agitation, tremor, hyperreflexia,
diaphoresis, and fever after continuing sertraline therapy. Which pharmacologic
mechanism best explains these findings?
